Over the past two decades great improvements in therapy of chronic inflammatory diseases have been made. The rise of TNFα biologics like infliximab has been a significant step forward to ameliorating disease course and keeping inflammations at remission levels for prolonged periods of time. Patients with too low drug concentrations have worse outcomes than those with adequate drug levels. Therapeutic drug monitoring (TDM) for infliximab is an important tool for the management of anti TNF therapy.
Patients with undetectable infliximab trough levels may exhibit the presence of anti-drug antibodies (ADA) which can block the effect of the drug. Fast detection of ADA supports guidance in the management of anti TNF therapy for rapid adaptations in the treatment regime.
Quantum Blue® Anti-Infliximab
The drug-sensitive Quantum Blue® Anti-Infliximab assay allows for a highly specific detection of antibodies against infliximab within 15 min. The ease of use and a short incubation time offer fast and reliable qualitative measurement of free anti-drug antibodies against the biologic drug.
The combination of the Quantum Blue® Infliximab and Quantum Blue® Anti-Infliximab rapid tests on the wide spread BÜHLMANN Quantum Blue® reader platform represents a complete solution for state-of-the-art therapeutic drug monitoring.
Quantum Blue® Anti-Infliximab Product Information